Maintenance Therapy with Votrient Provides Benefit in Advanced Ovarian Cancer

In a Phase III clinical trial, treatment with Votrient® (pazopanib) after initial chemotherapy improved outcomes among women with advanced ovarian cancer. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Ovarian cancer is often diagnosed at an advanced stage, highlighting the importance of finding new and more effective ways of treating this stage of the disease.

Votrient is an oral drug that blocks several biological pathways involved in the growth of tumors and new blood vessels. It is used for the treatment of advanced kidney cancer and advanced soft-tissue sarcoma.

To evaluate Votrient for the treatment of ovarian cancer, researchers conducted a Phase III clinical trial among 940 women with Stage III or Stage IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. All of the study participants had undergone surgery and initial chemotherapy. Women were only included in the study if chemotherapy had successfully prevented their cancer from worsening.

After completion of chemotherapy, study participants received either Votrient or a placebo daily for up to two years. Treatment that is given after a patient responds to initial treatment, but before cancer progression, is called maintenance treatment.

Maintenance treatment with Votrient improved progression-free survival (survival without the cancer worsening). Progression-free survival was 17.9 months among women treated with Votrient and 12.3 months among women treated with placebo. Side effects of Votrient included high blood pressure, diarrhea, nausea, headache, and fatigue.

These results suggest that maintenance treatment with Votrient delays cancer progression among women with advanced ovarian cancer. Longer-term follow-up will provide information about the effect of Votrient on overall survival.

Reference: Du Bois A, Floquet A, Kim JW et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international Intergroup trial (AGO-OVAR16). Presented at the 49th Annual Meeting of the American Society of Clinical Oncology. May 31-June 4, 2013; Chicago, IL. Abstract  LBA5503.

Copyright © 2013 CancerConsultants. All Rights Reserved.